Compare L3Harris Technologies Inc (LHX) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? L3Harris Technologies Inc trades at $239.35 (market cap $43.71B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: L3Harris Technologies Inc is far larger — about 8.4× Oruka Therapeutics Inc. Common Stock's market cap, and L3Harris Technologies Inc pays a 2.13% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| LHX | ORKA | |
|---|---|---|
Market Cap | $43.71B | $5.18B |
Volume | 1,558,148 | 490,798 |
Sector | Industrials | Health |
52-Week High | $378.48 | $113.08 |
52-Week Low | $233.63 | $26.19 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $54.15B | $4.31B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $237.50, down 0.31% with a bearish technical signal. The company shows solid fundamentals with consistent earnings beats, revenue growth from $21.3B to $21.9B (2024-2025), and a net income margin improving to 7.34%. Recent news includes a $6B THAAD propulsion contract but also multiple law firm investigations into investor claims, creating mixed sentiment.
Outlook: Strong defense budget tailwinds and recent contract wins support growth, but legal scrutiny and bearish technicals pose near-term risks. Analyst consensus is bullish with a $340 price target (43% upside), highlighting value if legal concerns resolve favorably.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
